REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents.
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2010
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms REASSURE
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
- 05 Nov 2008 Status changed from recruiting to discontinued, as reported by sanofi-aventis